In addition, preclinical studies and bioinformatic approaches suggest that breast tumors expressing low levels of BACH1 might be potentially sensitive to metformin treatment, while those enriched with BACH1 might be resistant to metformin treatment when administered as a single agent to manage tumors [10]. The gene discussed is BACH1; the disease is breast neoplasm.